All In Biotech

Drug Trial Radar · NCT00959764

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48-Week, Study of Oral Recombinant Salmon Calcitonin (rsCT) Compared to Salmon Calcitonin (sCT) Nasal Spray in Postmenopausal Osteoporotic Women

Last checked: Nov 20, 2026Latest source record: Nov 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 565 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

565

Actual

Start

Jun 2009

Primary completion

Feb 2011

Study completion Feb 2011

Sponsor

Lead sponsor
Tarsa Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness and tolerability of two medications, calcitonin nasal spray and a tablet containing calcitonin, in postmenopausal women with osteoporosis. Osteoporosis is the term used to describe a large group of diseases, which are characterized by loss of bone density, which makes the bones weaker. Osteoporosis often occurs in postmenopausal women. Calcitonin is a hormone found in the human body. Together with other substances, it regulates the concentration of calcium in the blood and inhibits the natural resorption of bone. Both medications in this study contain salmon calcitonin (sCT), because this form of calcitonin is more active than human calcitonin when used as a medicine. The calcitonin Nasal Spray used in this study is registered and available to doctors in United States for the treatment of osteoporosis. The medication being tested in this study is an oral tablet form of salmon calcitonin.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

  • Oral Calcitonin TabletsDrug

    Oral Calcitonin tablets along with matching placebo intranasal spray

  • Intranasal CalcitoninDrug

    Intranasal Calcitonin Spray

  • Placebo tablets and placebo intranasal sprayDrug

    Oral Placebo Tablets/Intranasal placebo spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar SpineTime frame: 48 weeks

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Rheumatology Associates of N. AL, P.C.

    Huntsville, Alabama

  • Northern California Institute for Bone Health, Inc.

    Oakland, California

  • Desert Medical Advances

    Palm Desert, California

  • Bethesda Health Research Center/Bone Health Center of Bethesda

    Bethesda, Maryland

  • 801 N. 30th Street, Suite 6718

    Omaha, Nebraska

  • New Mexico Clinical Research & Osteoporosis

    Albuquerque, New Mexico

  • Bone Mineral Research Center

    Mineola, New York

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • University of Wisconsin-Geriatrics & Endocrinology/Medical Sciences Center

    Madison, Wisconsin

  • Diagnostic Consultative Centre, "Sveta Anna" EOOD Sofia (Rheumatology Outpatient Office)

    Sofia, Sofia, Bulgaria

  • Synexus Hungary Ltd

    Budapest, Hungary

  • Synexus SCM Sp zoo

    Wroclaw, Wroclaw, Poland

  • Clinical Research Centres SA (Pty) Ltd

    Gauteng, Pretoria, South Africa

  • Synexus Thames Valley Clinical Research Centre

    Reading, Berkshire, United Kingdom

  • Synexus Midlands Clinical Research Centre

    Edgbaston, Birmingham, United Kingdom

  • Synexus Wales Clinical Research Centre

    Llanishen, Cardiff, United Kingdom

  • Synexus Lancashire Clinical Research Centre

    Chorley, Chorley, United Kingdom

  • Synexus Scotland Clinical Research Centre

    Clydebank, Glasgow, United Kingdom

  • Synexus Merseyside Clinical Research Centre

    Waterloo, Liverpool, United Kingdom

  • Synexus Manchester Clinical Research Centre

    Manchester, Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.